List of articles with "Palatin Technologies"

Palatin Q1 2026 Update

Palatin Q1 2026 Update

USA Palatin Technologies Princeton Obesity Treatment MC4R Agonists
Palatin's $18.2 Million Offering

Palatin's $18.2 Million Offering

USA biopharmaceuticals Palatin Technologies Princeton PTN
MC4R Agonist Data at ObesityWeek

MC4R Agonist Data at ObesityWeek

USA Atlanta Palatin Technologies MC4R agonist PL7737
Palatin's $15.8 Million Offering

Palatin's $15.8 Million Offering

USA Palatin Technologies Biopharmaceutical Princeton, NJ Public Offering
Palatin and Boehringer Ingelheim Deal

Palatin and Boehringer Ingelheim Deal

United States Boehringer Ingelheim Palatin Technologies Princeton Retinal Disease
Palatin Reverse Split

Palatin Reverse Split

United States Palatin Technologies Princeton OTCQB Reverse Stock Split
Palatin's PL7737 Results

Palatin's PL7737 Results

USA Palatin Technologies Princeton MC4R agonist PL7737
Palatin's Melanocortin Breakthrough

Palatin's Melanocortin Breakthrough

United States Palatin Technologies Diabetic Retinopathy Cranbury, New Jersey melanocortin agonists
Palatin Public Offering

Palatin Public Offering

USA Palatin Technologies Cranbury Biomedical Research OTC Market
PL9643 Progress Update

PL9643 Progress Update

Palatin Technologies Dry Eye Disease PL9643
Palatin Technologies Transition

Palatin Technologies Transition

United States Palatin Technologies Cranbury OTC Pink NYSE American
Palatin Secures Financing

Palatin Secures Financing

United States Palatin Technologies Cranbury NYSE American MC4R peptides
Palatin Launches Public Offering

Palatin Launches Public Offering

United States healthcare Palatin Technologies PTN Cranbury, New Jersey
PL9588 Dual Action Glaucoma

PL9588 Dual Action Glaucoma

United States Palatin Technologies Cranbury Glaucoma Treatment PL9588
Palatin's Phase 2 Study Results

Palatin's Phase 2 Study Results

United States Palatin Technologies Cranbury tirzepatide Bremelanotide
Palatin Appeals NYSE Delisting

Palatin Appeals NYSE Delisting

USA Palatin Technologies Cranbury NYSE Delisting Stock Compliance
Palatin Technologies Delisting

Palatin Technologies Delisting

United States Palatin Technologies Cranbury NYSE Compliance Delisting Appeal
Palatin's Phase 2b Results

Palatin's Phase 2b Results

United States Boston Palatin Technologies Diabetic Nephropathy Melanocortin Agonist
New Obesity Treatment

New Obesity Treatment

United States Palatin Technologies Cranbury tirzepatide Bremelanotide
Ulcerative Colitis Breakthrough

Ulcerative Colitis Breakthrough

United States Ulcerative Colitis Palatin Technologies PL8177 Cranbury
Palatin Q2 FY2025 Update

Palatin Q2 FY2025 Update

USA Palatin Technologies Cranbury tirzepatide MC4R agonist
Palatin's $4.7 Million Offering

Palatin's $4.7 Million Offering

United States Palatin Technologies Cranbury Biopharmaceutical stock offering
Obesity Trial Results

Obesity Trial Results

USA Palatin Technologies Cranbury GLP-1 tirzepatide MC4R bremelanotide
Palatin's 2025 Milestones

Palatin's 2025 Milestones

United States Palatin Technologies Cranbury tirzepatide MC4R agonist
BREAKOUT Study Success

BREAKOUT Study Success

United States Palatin Technologies Cranbury Bremelanotide Diabetic Nephropathy
Palatin Raises $3.4M

Palatin Raises $3.4M

USA Palatin Technologies Cranbury NYSE PTN Melanocortin
PL8177 Trial Update

PL8177 Trial Update

USA Ulcerative Colitis Palatin Technologies PL8177 Cranbury

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.